Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06877533 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by iTeos Belgium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT06877533 is a Phase 1 study that was terminated before completion, run by iTeos Belgium. The registered enrollment target is 3 participants.
The verdict
NCT06877533, a Phase 1 study, was terminated before completion, sponsored by iTeos Belgium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
TRM-010 is a first-in-human (FIH) clinical study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of EOS006215, a fully human monoclonal antibody that binds to the triggering receptor expressed on myeloid cells 2 (TREM2). The study includes EOS006215 monotherapy and combination therapy with other anticancer agents in participants with advanced solid tumors.
Interventions
- DRUG EOS006215
- DRUG Anticancer agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2025-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06877533
The ClinicalTrials.gov registry entry for NCT06877533 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is iTeos Belgium, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EOS006215 is the first listed.
NCT06877533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06877533 about?
NCT06877533 is a clinical study titled "A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors". TRM-010 is a first-in-human (FIH) clinical study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of EOS006215, a fully human monoclonal antibody that binds to the triggering receptor expressed on myeloid cells 2 (TREM2). T...
What is the current status of trial NCT06877533?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2025-04-07. Estimated completion is 2025-07-10.
What interventions are being tested in trial NCT06877533?
The interventions under investigation include: EOS006215 (DRUG), Anticancer agent (DRUG).
Who is sponsoring clinical trial NCT06877533?
This trial is sponsored by iTeos Belgium, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.